A Phase 1 interventional study of GSK1265744 Oral and GSK1265744 LAP 800mg intramuscular injection in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-10.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
LAI115428 is a Phase I, randomized, repeat dose escalation study to determine the safety, tolerability, and PK profile of intramuscular and subcutaneous injections of GSK1265744 in a long acting parenteral (LAP) formulation in healthy subjects. Subjects will be randomized to 3 monthly dosing cohorts and 1 quarterly dosing cohort with either intramuscular or subcutaneous dosing. In the monthly dosing cohorts subjects will receive GSK1265744 alone for 2 months and then in combination with TMC278 long acting parenteral (LA) for 2 months. For the quarterly dosing cohort, 2 quarterly intramuscular doses of GSK1265744 LAP will be given alone. Three dose levels of GSK1265744 will be evaluated partly in combination with TMC278 LA to adequately characterize the GSK1265744 LAP and TMC278 LA safety, tolerability, and PK profile. A total enrolment of approximately 40 healthy subjects is planned for this study.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 43 is below the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral GSK1265744 30mg once daily for 14 days
Drug: GSK1265744 Oral
GSK1265744 LAP injection given subcutaneously once a month for 4 months
Drug: GSK1265744 LAP 800mg intramuscular injection · Drug: GSK1265744 LAP 200mg subcutaneous injection
GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
Drug: GSK1265744 LAP 800mg intramuscular injection · Drug: GSK1265744 LAP 200mg intramuscular injection · Drug: TMC278 LA 1200mg intramuscular injection · Drug: TMC278 LA 600mg intramuscular injection
GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
Drug: GSK1265744 LAP 800mg intramuscular injection · Drug: GSK1265744 LAP 400mg intramuscular injection · Drug: TMC278 LA 1200mg intramuscular injection · Drug: TMC278 LA 600mg intramuscular injection
GSK1265744 LAP injection given intramuscularly once every 12 weeks.
Drug: GSK1265744 LAP 800mg intramuscular injection
30mg tablet
Also known as: GSK1265744
800mg Loading dose given at month 1 dose
Also known as: GSK1265744
200mg maintenance dose give at months 2 - 4
Also known as: GSK1265744
200mg maintenance dose given at months 2 - 4
Also known as: GSK1265744
400mg maintenance dose given at month 2 - 4
Also known as: GSK1265744
1200mg Loading dose given at month 3
Also known as: TMC278 LA
600mg Loading dose given at month 4
Also known as: TMC278 LA
800mg dose given quarterly (once every) 12 weeks
Also known as: GSK1265744
GSK1265744 LAP safety and tolerability parameters including the collection of adverse events
Time frame: approximately 25 weeks
GSK1265744 LAP safety and tolerability parameters including change from baseline in clinical laboratory safety assessments
Hematology, Clinical Chemistry and Urinalysis
Time frame: approximately 25 weeks
GSK1265744 LAP safety and tolerability parameters including change from baseline in electrocardiogram (ECG) measurements
Time frame: approximately 25 weeks
GSK1265744 LAP safety and tolerability parameters including change from baseline in vital sign measurements
Blood pressure and heart rate
Time frame: approximately 25 weeks
TMC278 LA safety and tolerability parameters including the collection of adverse events
Time frame: approximately 12 weeks
TMC278 LA safety and tolerability parameters including change from baseline in clinical laboratory safety assessments
Hematology, Clinical Chemistry and Urinalysis
Time frame: approximately 12 weeks
TMC278 LA safety and tolerability parameters including change from baseline in ECG measurements
Time frame: approximately 12 weeks
TMC278 LA safety and tolerability parameters including change from baseline in vital sign measurements
Blood pressure and heart rate
Time frame: approximately 12 weeks
Composite of PK parameters following single and repeat dose intramuscular or subcutaneous administration
Measurements include: area under the plasma concentration time curve over the dosing interval (AUC(0-t)), maximum observed concentration (Cmax), time to maximum observed concentration (tmax), concentration at the end of the dosing interval (Ct).
Time frame: approximately 25 weeks
Composite of GSK1265744 pharmacokinetic parameters following repeat dose oral administration
Measurements include: area under the plasma concentration time curve over the dosing interval (AUC(0-t)), maximum observed concentration (Cmax), time to maximum observed concentration (tmax), concentration at the end of the dosing interval (Ct).
Time frame: approximately 25 weeks
Composite of TMC278 LA pharmacokinetic parameters following single and repeat dose intramuscular administration
Measurements include: area under the plasma concentration time curve over the dosing interval (AUC(0-t)), maximum observed concentration (Cmax), time to maximum observed concentration (tmax), concentration at the end of the dosing interval (Ct).
Time frame: approximately 12 weeks
GSK1265744 LAP safety and tolerability parameters including change from baseline for clinical chemistry assessments (ALT, AST, ALP, Total and Direct Bilirubin).
Time frame: 52 weeks
GSK1265744 oral formulation safety and tolerability parameters including the collection of adverse events
Time frame: 21 days
GSK1265744 oral formulation safety and tolerability parameters including change from baseline in clinical laboratory safety assessments
Hematology, Clinical Chemistry and Urinalysis
Time frame: 21 days
GSK1265744 oral formulation safety and tolerability parameters including change from baseline in ECG measurements
Time frame: 21 days
GSK1265744 oral formulation safety and tolerability parameters including change from baseline in vital sign measurements
Blood pressure and heart rate
Time frame: 21 days
Composite of PK parameters of GSK1265744 LAP and TMC278 LA
Measurements include: apparent clearance (CL/FLAP) following single and repeat dose administration.
Time frame: approximately 12 weeks
Composite of PK parameters following each dose administration at different dose levels for the assessment of dose proportionality and relative exposure
Measurements include: GSK1265744 LAP AUC(0-t), Cmax, and Ct
Time frame: approximately 25 weeks
Composite of PK parameters for GSK1265744 LAP
Measurements include: apparent terminal phase half-life for LAP administration (t½), lambda z as a measure of absorption rate constant if data allow
Time frame: approximately 25 weeks
Composite of PK parameters of TMC278 LA
Measurements include: AUC(0-t), Cmax, and Ct in cohort 2 and 3
Time frame: approximately 12 weeks
The record gives a start of May 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir